000119413 001__ 119413
000119413 005__ 20240228134939.0
000119413 0247_ $$2doi$$a10.4161/cbt.29503
000119413 0247_ $$2pmid$$apmid:24918923
000119413 0247_ $$2pmc$$apmc:PMC4128861
000119413 0247_ $$2ISSN$$a1538-4047
000119413 0247_ $$2ISSN$$a1538-4077
000119413 0247_ $$2ISSN$$a1555-8576
000119413 0247_ $$2altmetric$$aaltmetric:2535714
000119413 037__ $$aDKFZ-2017-00155
000119413 041__ $$aeng
000119413 082__ $$a570
000119413 1001_ $$0P:(DE-HGF)0$$aAdwan, Hassan$$b0$$eFirst author
000119413 245__ $$aRiproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.G401
000119413 260__ $$aGeorgetown, Tex.$$bLandes Bioscience$$c2014
000119413 3367_ $$2DRIVER$$aarticle
000119413 3367_ $$2DataCite$$aOutput Types/Journal article
000119413 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1487772058_1763
000119413 3367_ $$2BibTeX$$aARTICLE
000119413 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119413 3367_ $$00$$2EndNote$$aJournal Article
000119413 520__ $$aRiproximin (Rpx) is a type II ribosome inactivating protein, which was investigated for its activity in pancreatic ductal adenocarcinoma (PDAC) in a panel of 17 human and rat PDAC cell lines and in rat pancreatic cancer liver metastasis. Cytotoxicity in response to Rpx was determined by MTT assay, apoptosis by flow cytometry and qRT-PCR for apoptosis related genes, and the modulation of the transcriptome was monitored by micro array analysis. The combination effect of Rpx and TRAIL was assessed by MTT assay. Rpx showed high but varying cytotoxicity in PDAC cells. Based on overall gene expression, the sensitivity of these cells was linked to genes involved in apoptosis. Furthermore, based on the affinity of Rpx for CEA, the expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) genes was significantly related to Rpx's cytotoxicity in cells with CEACAM gene expression. Exposure of Suit2-007 cells to Rpx induced the mRNA expression of members of signaling pathways initiating from most death receptors, and down modulation of TRAIL. Apoptosis was increased as shown by FACS analysis. Combination of Rpx with TRAIL resulted in a synergistic cytotoxic effect in human Suit2-007 and rat ASML cells, as evidenced by a 6-fold lower tumor cell survival than expected from an additive combination effect. Treatment of BDX rats bearing intra-portally implanted Suit2-007 cells showed a highly significant anticancer effect and indicated an application of Rpx against pancreatic cancer metastasis to the liver. These data favor further evaluation of Rpx as anticancer agent in PDAC.
000119413 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119413 588__ $$aDataset connected to CrossRef, PubMed,
000119413 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000119413 650_7 $$2NLM Chemicals$$aApoptosis Regulatory Proteins
000119413 650_7 $$2NLM Chemicals$$aPlant Proteins
000119413 650_7 $$2NLM Chemicals$$aTNF-Related Apoptosis-Inducing Ligand
000119413 650_7 $$2NLM Chemicals$$ariproximin protein, Ximenia americana
000119413 7001_ $$0P:(DE-HGF)0$$aMurtaja, Ahmed$$b1
000119413 7001_ $$0P:(DE-HGF)0$$aKadhim Al-Taee, Khamael$$b2
000119413 7001_ $$0P:(DE-He78)17064a887f14c1cee3ae16af3cf73314$$aPervaiz, Asim$$b3$$udkfz
000119413 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b4$$udkfz
000119413 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b5$$eLast author$$udkfz
000119413 773__ $$0PERI:(DE-600)2088895-8$$a10.4161/cbt.29503$$gVol. 15, no. 9, p. 1185 - 1197$$n9$$p1185 - 1197$$tCancer biology & therapy$$v15$$x1555-8576$$y2014
000119413 909CO $$ooai:inrepo02.dkfz.de:119413$$pVDB
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)17064a887f14c1cee3ae16af3cf73314$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119413 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119413 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119413 9141_ $$y2014
000119413 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER BIOL THER : 2015
000119413 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119413 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119413 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119413 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119413 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119413 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119413 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119413 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lToxikologie und Chemotherapie$$x0
000119413 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000119413 980__ $$ajournal
000119413 980__ $$aVDB
000119413 980__ $$aI:(DE-He78)G401-20160331
000119413 980__ $$aI:(DE-He78)C060-20160331
000119413 980__ $$aUNRESTRICTED